• Je něco špatně v tomto záznamu ?

The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology

X. Matias-Guiu, MR. Raspollini, J. Kulka, A. Ryska, R. Al Dieri, P. Schirmacher, European Society of Pathology (ESP)

. 2025 ; 486 (2) : 207-214. [pub] 20241217

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010064

Clinical trials in oncology are important tools to identify and establish new effective drugs for cancer treatment. Since the development of the concept of precision oncology, a huge number of multi-centric biomarker-driven clinical trials have been performed and promoted by either academic institutions or pharmaceutical companies. In this scenario, the role of pathologists is essential in multiple aspects, with new challenges that should be addressed. In this position paper of the European Society of Pathology, the role of pathologists as contributors to the design of the clinical trial, as local collaborators, or as members of central review laboratories is discussed. Moreover, the paper emphasizes the important role of pathologists in guiding methods and criteria of tissue biomarker testing in the biomarker-driven clinical trials. The paper also addresses issues regarding quality control, training, and the possible role of digital pathology.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010064
003      
CZ-PrNML
005      
20250429134835.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-024-04005-1 $2 doi
035    __
$a (PubMed)39690330
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Matias-Guiu, Xavier $u Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, CIBERONC, Lleida, Spain. fjmatiasguiu.lleida.ics@gencat.cat $u Hospital U de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain. fjmatiasguiu.lleida.ics@gencat.cat $1 https://orcid.org/0000000272016605
245    14
$a The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology / $c X. Matias-Guiu, MR. Raspollini, J. Kulka, A. Ryska, R. Al Dieri, P. Schirmacher, European Society of Pathology (ESP)
520    9_
$a Clinical trials in oncology are important tools to identify and establish new effective drugs for cancer treatment. Since the development of the concept of precision oncology, a huge number of multi-centric biomarker-driven clinical trials have been performed and promoted by either academic institutions or pharmaceutical companies. In this scenario, the role of pathologists is essential in multiple aspects, with new challenges that should be addressed. In this position paper of the European Society of Pathology, the role of pathologists as contributors to the design of the clinical trial, as local collaborators, or as members of central review laboratories is discussed. Moreover, the paper emphasizes the important role of pathologists in guiding methods and criteria of tissue biomarker testing in the biomarker-driven clinical trials. The paper also addresses issues regarding quality control, training, and the possible role of digital pathology.
650    _2
$a lidé $7 D006801
650    12
$a patologové $7 D000072142
650    12
$a nádory $x patologie $x farmakoterapie $7 D009369
650    12
$a nádorové biomarkery $x analýza $7 D014408
650    12
$a klinické zkoušky jako téma $7 D002986
650    _2
$a výzkumný projekt $x normy $7 D012107
650    _2
$a laboratorní medicína $x normy $x metody $7 D010338
650    _2
$a společnosti lékařské $7 D012955
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Raspollini, Maria Rosaria $u Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy
700    1_
$a Kulka, Janina $u Department of Pathology, Forensic and Insurance Medicine, Semmelweis University Budapest, Budapest, Hungary
700    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Al Dieri, Raed $u European Society of Pathology, Brussels, Belgium
700    1_
$a Schirmacher, Peter $u Institute of Pathology, University Hospital, Heidelberg, Germany
710    2_
$a European Society of Pathology (ESP)
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 486, č. 2 (2025), s. 207-214
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39690330 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134830 $b ABA008
999    __
$a ok $b bmc $g 2311434 $s 1247145
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 486 $c 2 $d 207-214 $e 20241217 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace